Hoth Therapeutics (NASDAQ:HOTH) Trading Down 3%

Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) were down 3% during mid-day trading on Thursday . The stock traded as low as $0.94 and last traded at $0.98. Approximately 320,189 shares traded hands during trading, a decline of 79% from the average daily volume of 1,503,875 shares. The stock had previously closed at $1.01.

Wall Street Analysts Forecast Growth

HOTH has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a report on Friday, August 16th. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st.

Hoth Therapeutics Trading Down 1.0 %

The company has a market capitalization of $5.20 million, a P/E ratio of -0.50 and a beta of 0.82. The firm’s 50 day moving average price is $0.82 and its two-hundred day moving average price is $1.04.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Friday, August 9th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.15. Analysts anticipate that Hoth Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.